Could diabetes drugs also protect kidneys by fixing fat?
NCT ID NCT07309094
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This study looks at whether GLP-1 drugs, used for diabetes and weight loss, can improve kidney health in people with chronic kidney disease. Researchers will measure changes in fat around the kidneys and heart, as well as kidney function. The goal is to see if these drugs reduce harmful fat-related inflammation that worsens kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vithas Valencia Consuelo
RECRUITINGValencia, Valencia, 46007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide) and SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin)
What this could lead to
If successful, this could show that GLP-1 drugs improve kidney health by reducing harmful fat around organs, pointing toward a better way to manage chronic kidney disease.
What could go wrong
This is an early-stage study with 250 people, so results may not apply to everyone. The drugs can cause side effects like nausea or stomach issues, and it's unclear if they will directly slow kidney damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.